Clinical trial
Phase 1/2A Study Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
NCT01690143 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1/2A Study Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
- Lead sponsor
- University of Alabama at Birmingham
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- May 31, 2012
- Completion date
- November 1, 2017
- Enrollment
- 45 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.